Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Ventilation 33% Improvement Relative Risk Oxygen therapy 46% c19regn.com Miyashita et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
Miyashita, 922 patient casirivimab/imdevimab early treatment study: 46% lower need for oxygen therapy [p=0.004] https://c19p.org/miyashita
copied to clipboard
Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
Miyashita et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.05.012
26 May 2022    Source   PDF   Share   Tweet
Retrospective 461 patients treated with casirivimab/imdevimab in Japan, and 461 matched controls, showing lower oxygen requirements with treatment.
Efficacy is variant dependent. Unlikely to be effective for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of mechanical ventilation, 33.3% lower, RR 0.67, p = 1.00, treatment 2 of 461 (0.4%), control 3 of 461 (0.7%), NNT 461.
risk of oxygen therapy, 46.4% lower, RR 0.54, p = 0.004, treatment 30 of 461 (6.5%), control 56 of 461 (12.1%), NNT 18.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Miyashita et al., 5/26/2022, retrospective, Japan, Asia, peer-reviewed, 6 authors, average treatment delay 4.0 days.
All Studies   Meta Analysis
This PaperCasirivimab/i..All
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit